874 related articles for article (PubMed ID: 25218739)
1. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
5. Imaging in multiple myeloma.
Delorme S; Baur-Melnyk A
Recent Results Cancer Res; 2011; 183():133-47. PubMed ID: 21509684
[TBL] [Abstract][Full Text] [Related]
6. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin D-lambda type multiple myeloma presenting with FDG-PET/CT negative bone marrow involvement.
Machida H; Shinohara T; Hino H; Yoshida M; Hatakeyama N; Okano Y; Inayama M; Hosokawa E; Abe S; Naruse K; Iwahara Y; Ogushi F
Intern Med; 2011; 50(14):1483-7. PubMed ID: 21757834
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
9. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?
Caldarella C; Isgrò MA; Treglia I; Treglia G
Int J Hematol; 2012 Dec; 96(6):685-91. PubMed ID: 23135876
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET in the evaluation of myeloma in 2012.
Bodet-Milin C; Eugène T; Bailly C; Lacombe M; Frampas E; Dupas B; Moreau P; Kraeber-Bodéré F
Diagn Interv Imaging; 2013 Feb; 94(2):184-9. PubMed ID: 23287424
[TBL] [Abstract][Full Text] [Related]
11. Whole-body (18)F-FDG PET identifies high-risk myeloma.
Durie BG; Waxman AD; D'Agnolo A; Williams CM
J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
Bhutani M; Turkbey B; Tan E; Korde N; Kwok M; Manasanch EE; Tageja N; Mailankody S; Roschewski M; Mulquin M; Carpenter A; Lamping E; Minter AR; Weiss BM; Mena E; Lindenberg L; Calvo KR; Maric I; Usmani SZ; Choyke PL; Kurdziel K; Landgren O
Leuk Lymphoma; 2016 May; 57(5):1114-21. PubMed ID: 26690712
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
[TBL] [Abstract][Full Text] [Related]
15. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X
Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772
[TBL] [Abstract][Full Text] [Related]
16. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
18. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.
Mulligan M; Chirindel A; Karchevsky M
Cancer Invest; 2011 Jun; 29(5):370-6. PubMed ID: 21599514
[TBL] [Abstract][Full Text] [Related]
19. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
20. Application of an artificial intelligence-based tool in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
